Related Experiment Videos
From dynamic to cellular cardiomyoplasty
Juan C Chachques1, Abdel Shafy, Fabricio Duarte
1Department of Cardiac Surgery, Ponpidou Hospital, Paris, France. j.chachques@brs.ap-hop-paris.fr
Insights
Dynamic cardiomyoplasty and cellular cardiomyoplasty show promise for treating heart failure. Improvements in surgical techniques and cell transplantation strategies are enhancing patient outcomes and myocardial function.
Area of Science:
- Cardiology
- Regenerative Medicine
- Surgical Innovation
Background:
- Heart failure remains a significant challenge, particularly in adult myocardium's limited repair capacity post-infarction.
- Current treatments for heart failure are often insufficient for patients refractory to medical therapy.
Purpose of the Study:
- To review advancements in dynamic cardiomyoplasty and cellular cardiomyoplasty for heart failure treatment.
- To explore the efficacy and potential of novel therapeutic strategies in cardiac repair.
Main Methods:
- Dynamic cardiomyoplasty involves using latissimus dorsi muscle, with recent improvements including mini-invasive techniques and growth factors.
- Cellular cardiomyoplasty explores transplantation of various cell types, including autologous myoblasts and bone marrow stem cells, into infarcted myocardium.
- Studies involve animal models of myocardial infarction and dilated cardiomyopathy, alongside ongoing clinical trials.
Main Results:
- Dynamic cardiomyoplasty has seen improved results with technical advancements, reduced mortality, and integration with electrophysiological therapies like cardiac resynchronization.
- Experimental cell transplantation studies show recovery of myocardial contractility, compliance, and improved diastolic function in animal models.
- Viable transplanted cells (myoblasts and myotubes) have been observed post-implantation.
Conclusions:
- Both dynamic and cellular cardiomyoplasty represent evolving therapeutic avenues for heart failure.
- Further clinical investigation is warranted to establish the long-term efficacy and safety of these cardiac regenerative approaches.
Abstract:
Dynamic Cardiomyoplasty. Latissimus dorsi dynamic cardiomyoplasty has been used in our institution for heart failure patients refractory to medical therapy; 113 cases were operated at Broussais and Pompidou Hospitals and 75 patients by our team abroad, in the scope of an international cooperative program. Cardiomyoplasty has been associated with better results due to technical improvements, the most significant mini-invasive techniques, the latest the use of growth factors to enhance muscle vascularization. Risk factors have been identified, resulting in more precise indications, a lower hospital mortality, and a wider use of this operation. There has been a new tendency to associate cardiomyoplasty with electrophysiological therapies: implantation of ventricular defibrillators and multisite cardiac pacing (for atrioventricular and interventricular resynchronization). Cellular Cardiomyoplasty. Adult myocardium cannot repair after infarction due to the absence of stem cells. Cell transplantation strategies for heart failure have been designed to replace damaged cells with cells that can perform cardiac work. Current possibilities in cell therapy for heart failure is the transplantation into the infarcted myocardium of autologous myoblasts (satellite cells originated from skeletal muscle), fetal cardiomyocytes, autologous heart cells, cells derived from bone marrow stem cells, and smooth muscle cells. Experimental studies demonstrated that cell transplantation into the myocardium was associated with the recovery of myocardial contractility and compliance, as well as the diastolic pressure-strain relationship in animal models (infarctlike myocardial lesions and dilated cardiomyopathy models). Healthy myoblasts and myotubes were observed 2 months after myocardial implantation. Clinical studies are now in progress.